Novo Nordisk Past Earnings Performance

Past criteria checks 6/6

Novo Nordisk has been growing earnings at an average annual rate of 14.9%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 14.1% per year. Novo Nordisk's return on equity is 78.5%, and it has net margins of 36%.

Key information

14.9%

Earnings growth rate

16.5%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate14.1%
Return on equity78.5%
Net Margin36.0%
Next Earnings Update02 May 2024

Recent past performance updates

Recent updates

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Mar 18
Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Dec 30
Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings

Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Dec 12
Novo Nordisk (CPH:NOVO B) Seems To Use Debt Rather Sparingly

Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Nov 24
Estimating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

Aug 20
Calculating The Intrinsic Value Of Novo Nordisk A/S (CPH:NOVO B)

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

May 22
Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

May 04
These 4 Measures Indicate That Novo Nordisk (CPH:NOVO B) Is Using Debt Safely

Novo Nordisk (CPH:NOVO B) Will Pay A Larger Dividend Than Last Year At DKK8.15

Feb 04
Novo Nordisk (CPH:NOVO B) Will Pay A Larger Dividend Than Last Year At DKK8.15

Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

Feb 02
Novo Nordisk (CPH:NOVO B) Has A Rock Solid Balance Sheet

Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jan 15
Estimating The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Revenue & Expenses Breakdown
Beta

How Novo Nordisk makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CPSE:NOVO B Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23232,26183,68361,59831,029
30 Sep 23214,49075,31258,06329,308
30 Jun 23201,32567,23956,59726,813
31 Mar 23188,29061,12953,01424,809
31 Dec 22176,95455,52550,68423,287
30 Sep 22167,19552,82548,41521,021
30 Jun 22157,25150,53945,94919,640
31 Mar 22149,02749,34443,02318,461
31 Dec 21140,80047,75741,05817,199
30 Sep 21134,60546,18339,20016,273
30 Jun 21129,91044,36238,23715,932
31 Mar 21126,87542,86437,55715,279
31 Dec 20126,94642,13836,88615,462
30 Sep 20127,22541,53736,69314,913
30 Jun 20126,57541,43336,28314,603
31 Mar 20126,60540,40336,49014,869
31 Dec 19122,02138,95135,83014,220
30 Sep 19119,33638,73135,05614,352
30 Jun 19116,82137,57434,34614,395
31 Mar 19114,19238,32233,85514,134
31 Dec 18111,83138,62833,31314,805
30 Sep 18110,09138,38432,72914,244
30 Jun 18108,94339,11732,06213,928
31 Mar 18110,17438,72531,73914,046
31 Dec 17111,69638,13032,12414,014
30 Sep 17113,27638,57631,78614,501
30 Jun 17114,19938,60932,26814,631
31 Mar 17113,02038,62632,39014,548
31 Dec 16111,78037,92532,33914,563
30 Sep 16111,08437,48432,46713,884
30 Jun 16110,33936,06432,49513,715
31 Mar 16109,93934,43932,81713,419
31 Dec 15107,92734,86032,16913,608
30 Sep 15103,63633,13130,71213,616
30 Jun 1599,09331,24829,57813,381
31 Mar 1593,66329,89927,87013,421
31 Dec 1488,80626,48126,76013,762
30 Sep 1485,91926,00526,57112,863
30 Jun 1484,18125,92026,15312,604
31 Mar 1483,93225,66026,44812,244
31 Dec 1383,57225,18426,88811,733
30 Sep 1382,83624,88626,51411,377
30 Jun 1382,17024,13826,22811,199
31 Mar 1380,25822,75025,56111,047

Quality Earnings: NOVO B has high quality earnings.

Growing Profit Margin: NOVO B's current net profit margins (36%) are higher than last year (31.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NOVO B's earnings have grown by 14.9% per year over the past 5 years.

Accelerating Growth: NOVO B's earnings growth over the past year (50.7%) exceeds its 5-year average (14.9% per year).

Earnings vs Industry: NOVO B earnings growth over the past year (50.7%) exceeded the Pharmaceuticals industry 4.7%.


Return on Equity

High ROE: NOVO B's Return on Equity (78.5%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.